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ABSTRACT
The immediate-early (IE) protein Vmwl75 (ICP4) of HSV-1 is
required for the transcription of later classes of viral genes
and the repression of IE gene expression. We have previously
constructed a panel of plasmid-borne insertion and deletion
mutants of the gene encoding Vmwl75 and assayed their ability
to regulate transcription in transient transfection assays.
By this approach we have mapped the regions of the Vrawl75 amino
acid sequence that are required for transcriptional activation
and repression of herpes virus promoters. This paper describes
the use of nuclear extracts, made from cells transfected with
these mutant plasmids, in gel retardation DNA binding assays
in order to define the regions of Vmwl75 involved in binding
to a specific Vrawl75 DNA binding site. The results show that
amino acid residues 275-495 (a region which is highly conserved
between Vmwl75 and the varicella-zoster virus "IE" 140K protein)
include structures which are critically required for specific
DNA binding, transactivation and repression. This raises the
interesting paradox that although the specific DNA sequence
recognized by Vmwl75 is not commonly found in its target
promoters, the protein domain required for recognition of this
sequence is required for promoter activation.
INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is a large complex
virus containing a double stranded DNA genome of around 150kb.
Upon infection of tissue culture cells the genes of HSV-1 are
expressed in a sequential cascade of three broad temporal
classes, defined as immediate-early (IE), early and late (1).
Expression of IE proteins is required for transcription of later
classes of genea (2,3,4) and there is evidence that at least
four of the five IE gene products are regulators of viral gene
expression (reviewed, 5). However, characterization of
temperature-sensitive (t£) and deletion mutations in these five
genes has revealed that only Vmwl75 (ICP4) and Vmw63 (ICP27)
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(the products of IE genes 3 and 2) are essential for virus growth
in cell culture (6-12). Functional Vtnwl75 is required for the
transcriptional activation of early and late genes and also the
repression of IE genes (13). Both of these activities can be
studied using cloned copies of IE gene 3 in transient
transfection assays to transactivate viral early gene promoters
or to repress expression from its own promoter (5).
Transactivation and repression have also been reproduced in vitro
using partially purified Vmwl75 (14,15).
Vmwl75 is a large, phosphorylated, nuclear protein (16)
which can be isolated as a homodimer (17). Whilst most of the IE
proteins bind to DNA to some extent in vitro (18) Vmwl75 is the
only one known to interact with specific target sequences which
include a proposed consensus binding sequence ATCGTC (15,19).
Vmwl75 has been shown to bind to this sequence in the promoter
regions of the IE1, IE3 and glycoprotein gD genes (19-22) but has
also been reported to bind to several viral DNA fragments which
lack the consensus (20,23). Evidence from a variety of
laboratories suggests a correlation between the ability of Vmwl75
to bind ATCGTC at the transcriptional start site of IE gene 3,
and autoregulation of this promoter. However, less is known
about the mechanism by which Vmwl75 transactivates promoters.
Most such promoters lack sequences closely related to the
consensus binding site, and indeed there is no evidence for any
transactivation specific promoter sequences being necessary for
the action of Vmwl75 (24-26). Recent evidence suggests that
Vmwl75 can also bind to alternative sites not related to the
consensus binding-site, both in promoter regions and the 5'
transcribed, non-coding regions of late genes (23); the
significance of this is not yet known.
IE gene 3 is present in two copies in HSV-1, being carried
on the repeat sequences bounding the short unique region of the
genome (27). The sequence of the gene reveals an uninterrupted
open reading frame encoding a protein of 1298 amino acids having
a predicted unmodified molecular weight of 133kDa (28). The
protein is homologous to a predicted 140kDa protein of a related
alphaherpesvirus, varicella-zoster virus (VZV) (28,29). The VZV
140K product is also a potent activator of transcription (24,30,
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unpublished results) and can complement HSV-1 mutants with ts
lesions in Vmwl75 (31,32). On the basis of the sequence homology
between the two proteins, and various other criteria, the Vmwl75
sequence has been divided into five structural regions, with
regions 2 and 4 containing the main regions of homology with the
VZV protein (28,29) (see Figure 3).
We have previously described the construction and functional
analysis of a large number of small, in-frame, insertion and
deletion mutants of a plasmid-borne copy of the gene encoding
Vmwl75 (33). By studying the activity of the resultant mutant
polypeptides in transient transfection assays we have defined the
regions of the protein which are important for repression of its
own promoter, and those important for transactivation of the
promoter of the HSV early gene encoding glycoprotein gD, in the
presence of another HSV-1 IE transactivator, VrawllO. Independent
analyses performed by DeLuca and Schaffer (34,35) using
chain-termination mutants of the gene encoding Vmwl75 in both
plasmids and recombinant HSV-1 virus have defined similar
functional domains.
This paper presents the results from further analyses of
plasmid-borne insertion and deletion mutants in Vmwl75. Extracts
were made from transfected cells and used in gel retardation
assays to measure the ability of each mutant polypeptide to bind
to a DNA probe containing the consensus Vmwl75-binding site at
the transcription start site of IE gene 3. The results show that
the regions of Vmwl75 required for DNA binding closely correspond
to those involved in transcriptional regulation. In particular,
a region crucial for site specific DNA binding lies within amino
acids 275-495.
MATERIALS AND METHODS
Plasmids. Plasmid pl75 expresses Vmwl75 under the control of the
SV40 early promoter and enhancer (36). Plasmids pill (36) and
p63 (37) express other HSV-1 IE gene products, VmwllO and Vmw63.
pGX38 carries the gene encoding the major DNA binding protein,
ICP8. The insertion mutant series pIl-39 was derived from pl75
by the insertion of 12bp EcoRI linkers at random restriction
sites and the deletion mutants were derived from these (33).
Deletions pD13, pD14 and pD15 were created by recombining pairs
of insertion mutants at the inserted EcoRI linker to generate
inframe deletions (see Table 2).
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Cell culture, infection and transfection. HeLa cells were
obtained from the ATCC through Flow Laboratories and grown in
Glasgow Modified Eagle's Medium containing 10% foetal ^alf serum.
The viruses used were derived from HSV-1 strain 17 syn (38).
Cells were infected at a multiplicity of infection of 5pfu per
cell and nuclear extracts made 5h after a In adsorption period.
Cells on 90 or 135mm plates (3 or 7x10 cells per plate) were
transfected by the procedure of Corsalo and Pearson (39). In
some recent transfections HBS was replaced by the more efficient
BBS (40). 30 or 60ug of pl75 derived plasmids were used plus 15
or 30ug of pOC9 as carrier. Nuclear extracts were made 45-50h
post transfection.
Preparation of nuclear extracts. Nuclear extracts of infected
and transfected cells were prepared by a procedure modified from
that of Dignam et al.,(41). Cells scraped from 135 or 9 0mm
culture dishes were washed in phosphate buffered saline (PBS) and
resuspended in 2 volumes buffer A plus 0.5% NP40 (lOmM Hepes
pH7.9, 1.5mM MgCl., lOmM KC1, 0.5mM DTT). After 10 minutes lysis
on ice nuclei werS pelleted by successive 2krpm/10 minute and
12krpm/20 minute spins in the Sorvall SS34 rotor. Proteins were
eluted from the nuclei by incubating for 30 minutes on ice in
2 volumes buffer C (20mM Hepes pH7.9, 25% glycerol, 0.42mM NaCl,
1.5mM MgCl,, 0.2mM EDTA, 0.5mM PMSF, 0.5mM DTT) before clearing
with a 30 minute ljjkrpm spin. The supernatants were flash frozen
and stored at -170 C.
Some whole cell extracts were produced by lysing cells with
buffer C plus 0.5% NP40; the results using extracts made by the
two methods were generally indistinguishable.
Determination of the relative quantities of Vmwl75 in nuclear
extracts. Nuclear extracts were assayed by the ELISA technique
in order to determine the relative amount of Vmwl75 present.
Microtitre wells were coated overnight with extract (5ul) plus
lOOul of a solution containing 0.05% sodium azide, 1% ovalbumin,
IS BSA, 0.1% Tween 20 in PBS. lOOul of a 1/5000 dilution of the
monoclonal antibody 58S (kindly supplied by M.Zweig, 42) was
adsorbed to the coated wells by shaking for lh at 3 7°C then lOOul
of a 1/3000 dilution of BIO-RAD horseradish peroxidase labelled
goat anti-mouse IgG was bound to this at 20 C for lh. Extensive
washes with PBS/0.1% Tween 20 were carried out between all steps.
The absorbance at 405nm was measured 10 minutes after addition of
substrate.
Gel retardation assay. The binding of Vmwl75 to the IE gene 3
cap site was assayed as described by Muller (22) using the gel
retardation DNA binding assay (43). The 45bp Ava I/BamHI DNA
fragment spanning the IE3 cap site (-17 to +27) was end labelled
by filling in using T4 DNA polymerase, separated on an 8%
polyacrylamide gel, eluted and purified through a Sephadex G-50
column. Binding reactions were generally carried out at 20 C for
20 minutes in a 20-30ul mix containing lug poly(dl).poly(dC),
about O.lng probe (2000cpm) and l-4ul nuclear extract (4-20ug
protein) in lOmM Tris.HCl pH7.6, lmM EDTA, 0.1% NP40. The
variation in final salt concentration (20-80mM NaCl) did not
affect the formation of the specific Vmwl75 complex, which is
stable up to at least 300mM NaCl (results not shown). The
complexes were resolved on 4% polyacrylamide gels, run in 0.5xTBE
buffer, which were dried before autoradiography.
11008
 at U
niversity of G
lasgow
 on D
ecem
ber 19, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research
Antibody shifts were carried out by incubating the binding
reaction for an additional 10-15 minutes after adding lul of a
1/100 dilution of monoclonal antibody 58S.
RESULTS
Vmwl75 in nuclear extracts made from transfected cells forms an
authentic complex with the IE gene 3 cap site.
We have used a gel retardation assay similar to that of
Muller (22) to show that nuclear extracts made from HeLa cells
transfected with a plasmid expressing HSV-1 Vmwl75 form a Vmwl75
specific complex with the IE3 cap site which is essentially
identical to that formed using extracts of virus infected cells.
Using a short end-labelled DNA probe spanning the cap site of
this gene a single major, viral specific, retarded complex is
detected on non-denaturing polyacrylamide gels after incubation
of the probe with infected cell nuclear extract for 20 minutes at
20 C (Figure 1A, tracks 3 and 4). This complex is further
retarded after additional incubation with the Vmwl75 specific
monoclonal antibody 58S (42) which recognizes an epitope near to
the C-terminus of Vmwl75 (33). These complexes were not formed
using extracts made from mock infected cells nor from cells
infected with an HSV-1 mutant which produces no Vmwl75, inl411
(44) (Figure 1A). The complex was also formed by extracts made
from cells infected with dll403, a mutant lacking both copies of
IE gene 1 which encodes VmwllO (8).
An apparently viral specific complex, labelled 'z', of much
greater mobility was occasionally formed (Figure IB), especially
if the binding reaction was carried out at elevated temperatures.
This complex was not further retarded by the antibody 5 8S,
indicating that it might be formed by a protein unrelated to
Vrawl75, or, by a proteolytic fragment of Vmwl75 lacking the
C-terrainal 58S epitope.
Extracts made from cells transfected with plasmid pl75,
which expresses HSV-1 Vmwl75, also formed a complex which was
usually indistinguishable from the viral specified complex and
which also contained Vrawl75 (Figure 2A). However, transfected
cell extracts occasionally formed two specific complexes which
were both recognized by 58S (Figure 2B). The smaller complex
could be formed by an abnormally processed form of Vmwl75 or it
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Figure 1; Autoradiograph of a gel retardation experiment showing
the protein-DNA complexes formed using nuclear extracts of HSV-1
infected cells bound to a DNA probe spanning bases -17 to +27
of the HSV-1 IE gene 3. Assays were performed as described in
the materials and methods, with (+) or without (-) addition of
monoclonal antibody 58S. Assays perfomed at (A) 20 C or (B) 40 C.
MI- mock infected, 17 - HSV-1 strain 17 , 1403= HSV-1 mutant
dll403, 1£11» HSV-1 mutant inl411, a- retarded complex containing
Vmwl75, a = complex a further retarded with antibody, b and c
are complexes containing host factors, z= novel retarded band,
probe= unbound DNA probe.
might lack an unknown factor. It usually appeared when the
overall efficiency of the transfections was poor and could
reflect a lower level of Vmwl75 in the transfected cells.
That cells transfected with pl75 formed a complex identical
to that formed with infected cell extracts indicates that Vmwl75
is the only viral protein present in the complex. No other HSV
proteins could be detected in the complex using monoclonal
antibodies (against the major DNA binding protein) or antipeptide
antisera (against VmwllO and Vmw63, results not shown). The
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Figure 2; Nuclear extracts containing Vmwl75 expressed in cells
transfected with plasmid pl75 form an apparently identical DNA
complex to that formed by Vmwl75 present in infected cell
extracts. (A) Binding assays were carried out as described in
Figure 1 using extracts of cells infected or transfected as
shown. Unbound probe has been cut off the bottom of the portion
of the gel shown. Plasmids used express Vmwl75 (pl75), VmwllO
(pill), Vmw63 (p63) and ICP8 (pGX38). (B) cells were transfected
with pl75 and the following plasmids: lanes 1 & 2, pill; 3 & 4,
pill and p63; 5 & 6, pill, p63 and pGX38; 7 & 8, pl75 alone.
a'= secondary complex, shifted to a' with antibody. (C) Addition
of extracts containing Vmw63 does not enhance Vmwl75 DNA binding.
Lane 1, pl75; lane 2, p63; lane 3 mix of extracts used in 1 & 2,
lane 4, cotransfection of pl75 and p63.
presence of other HSV-1 genes in the transfection had no effect
on the nature of complex formed, but addition of the gene
encoding Vmw63 did increase its amount (Figures 2A,B). However,
Vmw63 itself did not form a complex with this DNA probe, and the
addition of an extract containing Vraw63 to one containing Vmwl75
did not enhance binding (Figure 2C). Rather the effect of Vmw63
seemed to be on expression of Vmwl75, as the extract made from
Vmw63 and 175 encoding genes transfected together had 2.5 fold
more Vmwl75 than the extract from cells transfected with pl75
alone, as determined by ELISA.
The regions of Vtnwl75 important for DNA binding closely
correspond to those important for transcriptional regulation.
1. Analysis of insertion mutants. We have previously constructed
a series of derivatives of pl75 with twelve base pair insertions
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Figure 3; Map of the Vmwl75 coding sequence showing the position
of the Insertion and deletion mutants used in this study,
(a) Homology map of Vmwl75 in relation to VZV 140K. The three
main homology regions A, B and C are indicated. Clearly
homologous regions are shown as boxes, with the most homologous
sections filled (at least 80% identity), (b) Position of each
linker insertion (11-39) is represented by a vertical line,
(c) Colinear map showing the 5 regions of Vmwl75. (d) Extent
of deletions used in this study, dotted lines represent out of
frame sequences. The scale is given in amino acid residues.
at random sites in the Vmwl75 coding sequence (Figure 3) and used
these to define the regions of the protein that are important for
transactivation of an HSV-1 early promoter and repression of the
viral IE3 promoter (33). We have now investigated the DNA
binding activity of these mutants by using nuclear extracts made
from HeLa cells transfected with each of these 39 plasraids in gel
retardation assays.
Nuclear extracts were prepared from 7x10 transfected cells
and one twentieth (4ul) of each was incubated with the IE3 cap
site probe in a 30ul reaction volume at 20°C for 20 minutes, then
further incubated with lul 1/100 dilution of monoclonal 58S prior
to separation on 4% polyacrylamide gels. The resulting
autoradiographs are shown in Figure 4. The antibody shift was
carried out to clearly resolve the Vrawl75 complex from the
nonspecific complexes (b) and (c) although in some cases the
addition of antibody seemed to stabilize the degree of complex
formation (results not shown). In addition to the major (a )
complex, the minor (z) complex (Figure IB) was also occasionally
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Figure 4; Binding assays using extracts of cells transfected
independently with each of the 39 insertion mutants pll-pl39.
All assays were incubated with antibody 5 8S except M (mock
transfected) and pl75/- (positive control). Complexes a, a+,
b, c and z are as described in Figure 1.
present. The binding reactions were carried out at 20°C; at
higher temperatures the binding of wild type Vmwl75 was
significantly reduced (results not shown) although temperature
sensitive mutants can be studied in this manner (unpublished
results).
The amount of Vmwl75 in each extract was measured by ELISA
and compared to the pl75 control transfection to ensure that the
transfections were working with comparable efficiency and that
the Vtnwl75 polypeptide was present in the extract. These
results, together with a summary of the binding results in Figure
4, are presented in Table 1, which also summarizes the map
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Table 1. A Summary of the positions and Activities
of the Insertion Mutants.
Mutant
pll
pl2
PI3
PI4
pI5
pI6
PI7
pI8
PI9
pHO
pill
pI12
pI13
pI14
pI15
pI16
pI17
pI18
pI19
pI20
pI21
pI22
pI23
pI24
pI25
pI26
pI27
pI28
pL29
pI30
pI31
pI32
pI33
pI34
pI35
pI36
pI37
pI38
pI39
Insert
Site
12
71
83
123
130
137
161
229
252
275
292
310
324
329
337
373
398
438
494
518
561
591
649
681
774
787
803
843
934
943
1021
1066
1098
1133
1139
1195
1231
1236
1239
Trar sact. Repress.
activity" activity1"
x (SE)
35.1
53.4
49.6
65.6
43.8
54.4
44.5
45.7
127
25.8
30.8
20.0
10.0
4.9
4.5
16.5
11.8
15.5
49.2
47.2
43.4
26.2
23.9
21.1
38.2
80.9
45.9
10.8
3.4
48.2
22.4
10.3
30.0
20.8
48.2
86.9
47.5
63.1
51.1
(11.7) +++
(13) ++
(6.7) ++
(12.8) ++
(6.5) +++
(11.8) ++
(10.5) +++
(8) +++
(43.2) +++
(4.6)
(6.3) ++
(4.4) +
(2.9)
(0.9)
(0.9) +
(2.8)
(1.9)
(4.4)
(10.4) +++
(10.2) ++
(4.2) +++
(6.2) ++
(5.6) ++
(4.2) ++
(6.1) +++
(18.5) +++
(9.6) ++
(3.9) +++
(0.5) +
U2.3) ++
(3.7) +++
(3.0) +++
(8.9) ++
(2.3) ++
(13.6) ++
(18) +++
(10.3) +++
(11.2) +++
(8.6) +++
DNA Relative
binding . amount of
activity0 Vmwl75e
+++ 288
++ 203
+++ 88
+ •!-+ 2 4 1
+++ 106
+++ 103
+++ 29 7
+++ 127
+++ 263
++ 142
+++ 276
+/- 9 7
+++ 226
38
18
18
+ 39
+ 65
+++ 170
+++ 85
+-I-+ 294
+/- 206
++ 29 7
+/- 91
+++ 291
+++ 70
+ 126
+1- 15f
- 0f
+++ 5 8
+++ 100
+ 91
+ 15
++ 27
+++ 121
+++ 218
+++ 221
+++ 245
+++ 248
a The site (amino acid) of linker insertion.
b The activation of the gD promoter (using pgDCAT in conjunction
with vmwllO provided by pill) is given as a percentage of that
obtained in parallel experiments with pl75. The mean of at
least four independent determinations is given, with the
standard error of the mean. Wild type pl75 activated pgDCAT
expression 20-fold over uninduced levels (33).
c The qualitative ability to repress the IE3 promoter of plE3CAT
compared to pl75 in cotransfection titration experiments.
Repression activity is scored from - (essentially no activity)
to +++ (wild type activity) (33).
d The ability of nuclear extracts made from HeLa cells
transfected with each of the mutants to bind to the IE3 cap
site. Binding activity is scored from visual inspection of
Figure 4i - no binding, +/- barely detectable, + to +++
increasing binding activity.
e Relative amount of Vttiwl75 in each nuclear extract determined
by ELLISA. (pl75-100)
f Further experiments with this mutant did produce detectable
amounts of pI29 VHW175 as described in the text and Figure 5.
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positions and earlier transcriptional regulation results
published for these plasmids (33).
Table 1 shows that mutants impaired in their ability to bind
to the IE3 cap site in vitro broadly correspond to those impaired
in their ability to transactivate and to repress transcription in
transfection assays. For example insertion mutants pI12 to pI18
(with the exception of pI13) are all significantly reduced in the
transactivation and repression assays and also in their ability
to bind to the IE3 cap site. This is especially true of mutants
pI14-pI18. Indeed it is clear that this portion of the protein,
(region 2; amino acids 315-484) is of critical importance for
both transcriptional control and DNA binding. Only one mutant in
region 2, pll3, can efficiently bind to this DNA probe, but fails
to express either repression or transactivation activity.
Insertion mutants throughout the majority of region 1 are
virtually unimpaired in DNA binding activity or transcriptional
regulation. However, two mutants, pHO and pI12, situated at the
end of region 1 close to the junction with region 2, are
significantly reduced in their abilty to repress the IE3
promoter, and both are impaired in their ability to bind to the
IE3 cap site, pll2 markedly so.
However, DNA binding does not show an absolute correlation
with either transactivation or repression. For example two
insertion mutants in region 3, pI22 and pI24, are moderately
efficient transcriptional regulators, but bind to the IE3
promoter very poorly in vitro. Similarly several mutants in
region 4 have markedly reduced DNA binding activity, and whilst
some of these have deficient transactivation activity (p!28, p!29
and pI32) all except pI29 are fairly efficient repressors of IE3
expression. These individual descrepancies in the correlation
between DNA binding and transcriptional activity may reflect
differences between binding in vitro and in the nucleus of the
transfected cell.
One mutant, pI29, which failed to bind DNA in Figure 4
failed to produce detectable Vmwl75 in these initial nuclear
extracts. However, previous studies had detected low numbers of
cells expressing nuclear Vmwl75 by immunofluorescence of cells
transfected with pI29. When the transfections were repeated
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0175 pl29
+
-
Figure 5: An abnormal complex is formed by total cell extrgcts
of cells transfected with pI29. Binding is performed at 0 C
with (+) or without (-) addition of antibody 5 8S using whole
cell+extracts of cells transfected with pl75 or pI29. Complexes
a, a , b and c are as described in Figure 1, the novel complex,
n, formed by pI29 transfected extracts is shifted to n by
addition of antibody.
using BBS instead of HBS, detectable amounts of Vmwl75 could be
recovered and shown to bind to the IE3 cap site probe when
incubated at 0°C (Figure 5). However, the complex formed was of
reduced mobility both in the presence and absence of antibody.
This may indicate that the 129 mutation induces incorrect
processing or folding of Vmwl75. Total cell extracts of cells
transfected with pI29 had greater amounts of Vmwl75 binding
activity than nuclear extracts which may indicate that the
polypeptide encoded by pI29 is deficient in nuclear localization.
It is also possible that the protein expressed by pI29 is
unstable either in vivo or in vitro. The clustering of insertion
sites which result in plasmids producing reduced amounts of
Vmwl75 in nuclear extracts (Table 1) may indicate that certain
regions are important for protein stablity, for example the
regions of the protein defined by insertions 114-18, 128-30 and
133-34. Interestingly, mutations in the main DNA binding domain
(114-18) may result in a less stable protein. Apparently low
levels of protein expression do not of themselves explain poor
DHA binding since some extracts containing low levels of
ELISA-detectable protein are capable of normal DNA binding, for
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Mutant
pD13
pD14
pD15
pDl
pD2
pD2F
pD3
pD4
pD5
pD6
pD7
pD7F
pD8
pD9
pDll
pD12
Table 2.
Deleted
amino
acids
12-229
72-292
84-292
162-229
495-803
496-803
518-591
518-1133
562
592-774
650-1066
650-1066
682-774
934-1098
1196-1239
1232-1269
A Summary
of
of the Extent and
the Deletion Mutants.
Framea IIFb
IN
IN
IN
IN
OUT
IN
IN
IN
OUT
IN
OUT
IN
IN
IN
IN
IN
n.d.g
n.d.
n.d.
nuc.
_
cyt.
nuc.
cyt.
-
cyt.
-
cyt.
cyt.
nuc.
nuc.
nuc.
Transact. Repress
act. act.a
X
30
23
5
4
18
3
29
27
10
57
4
6
7
(SE)
n.d. n.d.
n.d. n.d.
n.d. n.d.
(4.8) +++
(4.0)
(0.5) +
(0.5) +++
(3.3) ++
(1.3) ++
(2.8) +
(5.4)
(1.5) +
(5.6)
(0.6) +++
(2.2) +++
(2.2) ++
Activities
. DNA
binding
act.§
weak
-
-
+
-
weak
-
-
-
weak
-
-
weak
+
+
+
Relative
amount,of
Vmwl75
25
14
15
216
n.d.
52
107
27
n.d.
25
n.d.
88
95
13
59
52
a Phase of reading frame 3' to deletion
b Cellular localization of protein as determined by
immunofluorescence (33). nuc. nuclear, cyt. cytoplasmic,
- not detectable by immunofluorecence
c The activation of the gD promoter as described in Table 1
(and ref. 33).
d The qualitative ability to repress the IE3 promoter as
described for Table 1 (and ref. 33).
e The ability of whole cell extracts made from cells transfected
with each of the mutants to bind to the IE3 cap site probe in
gel retardation assays (at 0 C). Binding is scored simply as
positive (+), negative (-) or weak,
f Relative amount of Vmwl75 in each nuclear extract determined
by ELISA. (pl75»100, the results are given for the extracts
used in Figure 6, or, in the case of the non-binding mutants,
for extracts containing the most Vmwl75; out of frame proteins
could not be detected by ELISA.)
g n.d. not done
example pl34 and the deletion mutant pD9 (Table 2). It is also
possible that the low ELISA measurements could be explained by
failure to efficiently extract or detect mutant polypeptides if,
for example, insertions effect protein solubility or expression
of the 58S epitope.
2. Analysis of deletion mutants. We have previously described
the construction of a number of in frame deletion mutants within
the Vmwl75 coding region using the inserted EcoRI sites (33).
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These mutants were assayed for their ability to bind to the IE3
DNA probe at 0°C in order to increase the sensitivity of the
assay. These results are presented in Table 2 with the
previously published results from transcription and
immunofluorescence assays and the relative amount of ELISA
detectable protein in each extract. Transfections were repeated
at least three times for those extracts which failed to bind DNA
and the highest ELISA measurement recorded.
DeLuca and Schaffer (35) have previously reported that a
truncated polypeptide, encoding only the first 590 amino acids of
Vrawl75, is able to bind to DNA under some conditions. The
results presented in Table 2 and Figure 6 confirm their results
and allow us to map more finely the regions of Vmwl75 unimportant
for DNA binding.
Plasmids which expressed variants of Vmwl75 with some DNA
binding activity all have deletions which do not include amino
acids 229-495, (Table 2, Figure 6). Whilst not all plasmids with
deletions lying totally outwith this region express binding
competent proteins (for example pD3, pD5 and pD7F) individual
deletions which do not completely abolish DNA binding cover most
of the rest of the gene (deletions 1, 2F, 6, 8, 9, 11, 12 and 13;
Table 2). Because large deletions of the protein may cause many
unpredictable changes in protein stability and conformation,
perhaps only those deletions which do not totally abolish DNA
binding activity should be considered significant results. The
results with the deletion mutants, therefore, confirm the
conclusion from the insertion mutant assays that the main DNA
binding domain of Vmwl75 centres around region 2.
The correlation between the DNA binding, transactivation and
repression activities of the deletion mutants is less clear than
with the insertion mutants (Table 1). However, the results with
the deletion mutants do not separate any protein regions uniquely
involved in each activity. It is perhaps suprizing that there
are mutants which, although unable to bind to DNA in our assay,
are able to activate repression. It is possible that such
mutants retain some DNA binding capability in the cell. These
mutants are severely impaired in their ability to transactivate,
and therefore demonstrate overlap between the protein domains
11018
 at U
niversity of G
lasgow
 on D
ecem
ber 19, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research
p175 D1 1 2f 2f 6 D8 09 11 12 13
b-
Figure 6: Binding assays performed at 0°C with antibody shift,
using total cell extracts of cells transfected with deletion
mutation plasraids pDl-15 (see Table 2). Only mutants with some
detectable binding activity are shown. The wild type (pl75)
shifted complex (a ) is labelled, as are the host derived
complexes b and c; weak complexes are highlighted.
required for at least two of the three functions assayed.
Interestingly, deletions in regions 4 and 5 (pD9, Dll and
D12) give rise to somewhat larger DNA complexes than that formed
by wild type Vmwl75, although these deletion plasmids are
predicted to express proteins of a lower molecular weight.
As suggested above for the insertion mutant pI29 this might be
caused by a partial denaturation of these mutant polypeptides
in vivo or in vitro. Some proteins deficient for nuclear
localization (pD2F, D6 and D8) were able to bind to the 1E3
probe, albeit very weakly, when extracts were prepared from whole
cells (Figure 6); nuclear extracts of these deletion mutants did
not contain significant amounts of Vmwl75 (results not shown).
It is also noteworthy that deletions pDl and pD13 which remove a
serine rich phosphorylation site in region 1 are also able to
bind DNA.
DISCUSSION
In order to investigate the relationship between the
functional activities of Vtnwl75 and its site-specific DNA binding
property a panel of 39 in-frame insertion and sixteen deletion
mutants were assayed for their ability to bind a DNA probe in
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vitro. These mutants had previously been assayed for their
ability to transactivate and repress herpes gene expression in
transient assays (33). These studies had shown that two large
regions, 2 and 4 in Figure 3, which are highly conserved between
Vmwl75 and the VZV "IE" protein 140K (28,29), do indeed
correspond to important functional regions. Whilst region 2
seems to be of critical importance for both transactivation and
repression functions, region 4 seems to be of lesser importance
for repression.
Although the results presented in this paper do not
demonstrate an absolute correlation between in vitro DNA binding
activity and either transactivation or repression, it is clear
that the general regions of the protein involved in all three
phenotypes are similar. In particular the integrity of region 2
is of critical importance for each property investigated,
excepting nuclear localization.
Previous studies have attempted to map the regions of Vmwl75
involved in DNA binding by a variety of approaches. Kristie and
Roizman (21) have reported that binding of monoclonal antibody
H950 to Vmwl75 abolishes DNA-binding activity. The epitope for
this antibody has been mapped to within amino acids 21-36 (45)
and therefore lies within a section of region 1 shown not to be
required for DNA binding both by our results (Tables 1 and 2) and
also by DeLuca and Schaffer (35). Therefore it is likely that
the antibody is blocking DNA binding through longer range steric
affects.
Hubenthal-Voss et al., (45) have also attempted to map the
DNA binding domain of Vmwl75 by using short synthetic
oligopeptides to interfere or compete with functional sites for
binding the recognition sites in the IE1 fc»0) promoter. Their
results, which mapped regions important for DNA binding activity
near to the amino terminus, are at variance with our results.
Indeed we show that the region they investigated seems to be of
little importance, at least in binding the IE3 («4) recognition
site.
DeLuca and Schaffer (35) have used a set of viral mutants
expressing truncated forms of Vmwl75 to map the DNA binding
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domain. The results obtained with their panel of deletion and
nonsense mutants allowed them to present a map of the functional
domains of the protein which is in good agreement with our own
results presented here and previously (33). Mutants deleting the
first 9 0 amino acids of the protein and those removing residues
downstream from 773 were essentially wild type in their ability
to bind an IE3 promoter DNA probe, and in their capacity to
regulate IE3 and early gene transcription, although viruses
encoding the downstream deletions were somewhat impaired in late
gene expression. A mutant deleted from amino acid 590 was able
to form a novel DNA complex at elevated salt concentrations, but
possesed no regulatory actvity in the virus.
However, this approach lacks sensitivity unless applied from
both the amino and carboxyl termini, and truncated proteins may
exhibit conformational abnormalities making interpretation of
results more complicated. Indeed from the results of our assays
it is apparent that the insertion mutants give a more consistent
pattern of results, and perhaps with the larger deletions only
positive results should be considered significant. Our deletions
pD13, pDl and pD2F show that amino acids outside residues 229-49 6
are probably not directly involved in site-specific DNA binding.
Those mutant polypeptides with insertions and deletions outwith
this region which fail to bind DNA may be inactivated by longer
range steric effects, for example disruption of protein folding.
Under the conditions of binding used by DeLuca and Schaffer
(35) the Vmwl75 DNA complexes were salt labile when the
concentration was raised from 15 to 65mM NaCl. Furthermore they
observed that some of their mutants formed novel complexes at
elevated salt concentrations. We did not observe this salt
lability under our conditions of binding and indeed the wild type
Vmwl75 DNA complex was stable up to 300mM NaCl (results not
shown). Nor did we see any novel complexes formed at higher salt
concentrations although these experiments were not performed on
each mutant. We confirm their observations that deletion of the
nuclear localization site, centred around amino acid 728 (33,35),
did not prevent DNA binding of mutant protein recovered from the
cytoplasm.
11021
 at U
niversity of G
lasgow
 on D
ecem
ber 19, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research
Michael et al (23) have recently reported that different
post-translationally modified forms of Vmwl75 possess different
binding affinities for DNA probes which do not include an ATCGTC
consensus. DeLuca and Schaffer (35) have shown that the serine
rich tract in homology region A, which is conserved between VZV
and HSV, is probably the major site of phosphorylation for this
protein. However, we have shown that deletion of this region
does not abolish affinity for the IE3 probe which includes the
ATCGTC consensus, nor is this region essential for
transactivation or repression (33). Interestingly, it has
recently been reported that the serine phosphorylations of the
adenovirus Ela protein do not affect transactivation or
repression (46).
Because the regions of Vtnwl75 required for transcriptional
activation and repression overlap with each other and with the
region required for site-specific DNA binding we have not been
able to directly associate site-specific binding uniquely with
either regulatory activity. The weight of experimental evidence
supports a role for the Vmwl75 binding site at the cap site of IE
gene 3 in autoregulation but it is still an enigma as to why the
same protein sequences should apparently mediate this function
and trancriptional activation which is not sequence specific.
It is possible that Vmwl75 possesses a second less specific DNA
binding activity, perhaps encoded by the same protein sequences
or alternatively elsewhere in the protein. Indeed Michael et al
(23) have observed Vmwl75 binding to the 5' transcribed
non-coding regions of late genes which do not possess the
consensus site-specific binding site. It will be interesting to
investigate which regions of the protein are required for this
activity, and whether these coincide with the regions (4 and 5)
identified by DeLuca and Schaffer as being involved in late gene
activation (35,47).
The precise functional role of regions 4 and 5 of Vmwl75
is still obscure. We have previously shown that insertions and
deletions in these regions interfere with transactivation and
repression in a complicated manner (33) although clearly some
mutants with large deletions in this region still encode proteins
functional in transfection assays (34,48) and in recombinant
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virus (35). Whether this portion of the coding sequence is
simply important for conformational stability of the protein, or
whether it directs a novel, uncharacterized activity is unknown.
However, the strong conservation of region 4 between VZV and HSV,
and the occurence of many temperature sensitive mutations in this
region (13,47,49, unpublished results) suggests that this region
does perform an essential role in the virus life-cycle.
Taking into consideration the known properties of Vmwl75
it is possible to propose a simple functional model that could
account for its dual roles of transcriptional activator and
repressor. The model proposes that Vmwl75 interacts
simultaneously both with DNA and with host trancription factors,
such as the TATA box binding factor TFIID (50,51), in order to
produce a functional stabilized transcription complex. If the
DNA binding region of Vmwl75 encounters a very strong binding
site sequence, such as that at the IE3 cap site, then the high
affinity constant of the DNA/Vmwl75 complex could effectively
immobilize the transcriptional machinery. If the DNA sequence is
less strongly bound by Vmwl75, then the stabilized transcription
complex would be free to proceed. Note that the proposed site of
interaction with the host proteins may also map in region 2
which, at over 200 amino acids, is of itself almost as large as
the adenovirus Ela protein. Thus the same region of the protein
could be important for transactivation, repression and DNA
binding. This model is consistent with the importance of the
TATA/cap region for activation of the tk promoter (26) and the
binding of Vmwl75 to (non-consensus and possibly weak) sites in
the 51 untranslated regions of other activated HSV genes (23).
This model can be tested experimentally.
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